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Background: The aim of the study was to assess the relationship between computed tomography 
(CT) densitometry and routine clinical markers in patients with chronic obstructive pulmonary 
disease (COPD) and alpha-1 anti-trypsin deficiency (AATD).
Methods: Multiple databases were searched using a combination of pertinent terms and those 
articles relating quantitatively measured CT densitometry to clinical outcomes. Studies that used 
visual scoring only were excluded, as were those measured in expiration only. A thorough review 
of abstracts and full manuscripts was conducted by 2 reviewers; data extraction and assessment 
of bias was conducted by 1 reviewer and the 4 reviewers independently assessed for quality. 
Pooled correlation coefficients were calculated, and heterogeneity was explored.
Results: A total of 112 studies were identified, 82 being suitable for meta-analysis. The most 
commonly used density threshold was -950 HU, and a significant association between CT 
density and all included clinical parameters was demonstrated. There was marked heterogene-
ity between studies secondary to large variety of disease severity within commonly included 
cohorts and differences in CT acquisition parameters.
Conclusion: CT density shows a good relationship to clinically relevant parameters; however, 
study heterogeneity and lack of longitudinal data mean that it is difficult to compare studies or 
derive a minimal clinically important difference. We recommend that international consensus 
is reached to standardize CT conduct and analysis in future COPD and AATD studies.
Keywords: computed tomography, CT, densitometry, emphysema, chronic obstructive 
pulmonary disease, alpha-1 anti-trypsin deficiency
Plain language summary
Computed tomography (CT) produces a digital image that is reconstructed into the recogniz-
able picture format. CT densitometry describes the method that uses using this information to 
accurately quantify the severity of emphysema, and this has been validated pathologically and 
clinically. However, CT densitometry is yet to be standardized and its clinical utility remains 
unclear. This systematic review has highlighted the vast heterogeneity that exists between 
studies using CT density, and despite the strong relationship to clinically relevant parameters, 
international consensus is still required to standardize CT conduct.
Introduction
The heterogeneity of chronic obstructive pulmonary disease (COPD) and alpha-1 
anti-trypsin deficiency (AATD) is well recognized, as is the need for more descriptive 
biomarkers beyond lung function.1 Computed tomography (CT) has been used for 
many years to visually diagnose emphysema, providing the most direct assessment 
of its presence and distribution.2 Software programs have since been developed, 
which can objectively measure the severity of emphysema.3 Quantitative CT, and 
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in particular CT densitometry, is the method of quantifying 
emphysema using such software; its ability to assess emphy-
sema has been validated clinically and pathologically.4–6 
However, CT densitometry is yet to be standardized, with 
numerous factors impacting on the measurement of density 
and affecting results.7 Changes seen on CT predate those 
seen on spirometry, with pathological studies demonstrat-
ing that up to one-third of the lung tissues is destroyed in 
emphysema before spirometry becomes abnormal. This 
suggests that CT densitometry may be a very important 
technique for detection of early disease, an area which is 
of increasing clinical interest.8 CT densitometry was the 
primary outcome measure for registration level randomized 
clinical trials (RCTs) of augmentation therapy in AATD, 
where signals have been seen for this measure, and only 
trends in the same direction for other clinical outcomes.9 
More recently large cross-sectional studies in COPD have 
been established (eg, COPDGene), which have collected 
data from quantitative measures on CT as well as extensive 
physiology.10
Understanding the implications of density data is complex 
for both clinicians and regulatory agencies and no systematic 
reviews of its utility have been undertaken. The purpose of 
our study was to assess the validity of CT densitometry as 
a measure of severity and progression of lung disease in 
emphysema specifically seeking relationship to lung function, 
mortality, hospital admissions and quality of life (QOL).
Methods
This review is registered with Prospero (CRD42015024183). 
All papers concerning patients with clinically or spirometri-
cally defined COPD that compared CT densitometry data 
with FEV
1
, gas transfer (diffusing capacity of the lungs for 
carbon monoxide [DLCO] or transfer factor divided by the 
alveolar volume [KCO]) and QOL, in the same study popu-
lation were included. In addition, any study that described 
longitudinal density change, irrespective of whether there 
was a direct relationship to one of our pre-specified outcomes, 
was included. Studies in which COPD was secondary to 
AATD were included.
Population
The following databases were searched with no date or lan-
guage restrictions: MEDLINE (Ovid), MEDLINE In Process 
(Ovid), EMBASE (Ovid), Cochrane Library (Wiley) Cochrane 
Central Register of Controlled Trials (CENTRAL), CMR, 
CDSR, HTA, NHS EED and DARE. In addition, Conference 
Proceedings Citation Index via Web of Science and British 
Library’s ZETOC was searched for conference proceedings 
and abstracts, and ClinicalTrials.gov and WHO International 
Clinical Trials Registry Platform were searched for ongoing 
trials. Search terms for COPD and AATD were combined with 
all search terms for CT or CT densitometry, and lung function 
(see Supplementary materials for full search terms).
study selection
Titles and abstracts of search yield were screened for rel-
evance by 2 reviewers independently. Disagreements were 
resolved by discussion, where required involving a third 
reviewer. Relevant articles were obtained and assessed 
against the full selection criteria in a similar manner (see 
Supplementary materials for full inclusion and exclusion 
criteria). Studies that used visual scoring only were excluded, 
as were those measured in expiration only.
Data extraction
Data were extracted using the Cochrane model, and included 
general study information, specifics of CT acquisition (ie, 
reconstruction algorithm, software and slice thickness), 
percentage low attenuation area (%LAA), whether the scan 
was taken in full inspiration, use of bronchodilator during 
spirometry and a CT phantom for quality assurance.11 This 
process was performed by 1 reviewer (DC) and checked by 
the remaining authors.
risk of bias
Risk of bias was assessed by one reviewer (DC) and inde-
pendently by AMT, MR, MK, and EL using a mixture of 
two recognized bias tools (Table S1). The AHRQ was used 
in order to accurately examine the large amount of cross 
sectional studies included, and QUADAS 2 where CT density 
is being considered as a diagnostic tool.12,13 Publication bias 
was assessed using funnel plots and Begg-Mazumdar/Egger 
tests, and efforts were made to reduce publication bias by 
using no date or language limits.
Data synthesis
Baseline characteristics are presented as mean (standard 
deviation) or median (interquartile range). Studies where 
density was taken from a single slice, where there was divi-
sion into arbitrary emphysematous thresholds or that quoted 
mean lung density only were excluded. Studies that com-
pared CT density with one of our chosen clinical parameters 
using Pearson’s correlation coefficient were meta-analyzed 
to estimate the Schmidt-Hunter (SH) weighted mean cor-
relation coefficient. As SH is a random effects model, it is 
suitable for heterogeneous populations, with weighted means 
to accurately account for the variance.14 I2 and chi-square 
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analyses were performed to assess study heterogeneity. 
All analyses were performed using StatsDirect, and where 
meta-analysis was not possible, a narrative synthesis is 
provided.
Results
The PRISMA flow diagram (Figure 1) demonstrates that 
112 papers were included in the overall narrative, and 
82 papers could be combined in a quantitative meta-analysis. 
A small number of papers reported lobar densities, which 
were analyzed separately (Table S2). Characteristics of all 
included papers can be found in Table S3.
Cross-sectional studies of CT density
Pulmonary function tests
Table 1 summarizes the baseline characteristics of studies 
and patients included in meta-analyses. %LAA at -950 HU 
was the most commonly used emphysematous threshold, with 
55 individual studies reporting the association between -950 
and clinical parameters, of which 23 were from larger cohort 
studies (eg, COPDGene, KOLD).10,14
spirometry
FeV1
A total of 36 studies compared forced expiratory volume in 
1 second (FEV
1
) percent predicted to CT density. The forest 
plot in Figure 2 demonstrates the correlation between FEV
1
 
percent predicted with CT density at -950 HU, and the varia-
tion between the included studies. These data are summarized 
in Table 2, which shows meta-analyses of the other CT param-
eters against FEV
1
 (L) or FEV
1
 percent predicted. The level of 
heterogeneity remained high in all sub-group analyses except 
for 900 HU and FEV
1
 percent predicted, which contained the 
smallest number of studies and thus could be less reliable.
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Figure 1 PRISMA flow diagram.
Abbreviations: CenTral, Cochrane Central register of Controlled Trials; CT, computed tomography; COPD, chronic obstructive pulmonary disease; aaTD, alpha-1 
anti-trypsin deficiency.
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Table 1 summary of all studies included in meta-analyses
Statistical  
method
Density  
measure
No of   
studies
No of   
patients
Age FEV1pp DLCOpp KCOpp
Correlation  
coefficient
-900 7 551 66 (10) 54.96 (20.19) 65.47 (20.97) 63.73 (20.13)
-910 2 69 64.67 (8.34) 58.93 (24.27) 57.46 (19.63) 61.59 (22.47)
-950 46 10,764 62.45 (10.77) 58.04 (33.59) 59.90 (31.43) 85.19 (21.86)
-960 6 639 67.96 (8.76) 54.86 (23.75) – –
PD15 7 4,544 60.91 (9.22) 53.99 (24.52) – 67.16 (24.58)
Multivariate  
regression
-910 3 425 62.04 (8.93) 64.17 (27.27) – –
-950 14 18,984 60.59 (9.56) 78.71 (26.29) 66.23 (23.44) 87.06 (18.07)
-960 2 161 70.33 (8.69) 54.81 (20.13) – –
PD15 8 7,251 59.89 (9.51) 93.06 (20.63) – 85.19 (18.86)
Trials
•	 ICs ±	laBa -950 2 482 64.50 (7.37) 50.50 (12.21) 75.15 (29.50) 46.70 (39.08)
•	 aTra PD15 2 375 58.83 (9.91) 44.99 (15.70) 43.82 (14.79) 43.70 (13.57)
•	 Prolastin PD15 4 369 51.83 (7.39) 47.39 (12.35) 36.14 (23.39) 54.70 (11.77)
Mortality Mixed 6 3,584 61.66 (9.68) 69.39 (31.27) – –
exacerbations Mixed 7 2,637 66.10 (8.22) 60.54 (25.44) – –
sgrQ Mixed 8 4,864 58.82 (13.75) 45.01 (19.03) 35.68 (18.17) 60.40 (22.22)
BODe Mixed 4 2,440 65.58 (6.44) 44.43 (21.19) 35.08 (19.87) –
6MWT Mixed 3 2,481 61.63 (9.38) 56.03 (48.57) – –
MrC Mixed 4 694 64.84 (10.85) 56.97 (18.99) – –
Notes: studies of lung function, sub-divided by statistical techniques, were used to assess relationship to CT density, followed by trials, and those using quality of life 
measures. all quantitative measures are shown as mean (sD). ‘–’ indicates data not available.
Abbreviations: FeV1, forced expiratory volume in 1 second; DlCO, diffusing capacity of the lungs for carbon monoxide; KCO, transfer factor divided by the alveolar 
volume; pp, percent predicted; PD15, 15th percentile point; ICs, inhaled corticosteroid; laBa, long-acting beta agonist; aTra, all-trans retinoic acid; sgrQ, st georges 
Respiratory Questionnaire; BODE, BMI, airflow obstruction, dyspnea and exercise tolerance; 6MWT, 6-minute walk test; MRC, Medical Research Council; CT, computed 
tomography.
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Figure 2 Forest plot of all studies included in the meta-analysis that correlated FeV1 percent predicted with -950 hU.
Notes: The ranges of correlation coefficients are from -0.09 to -0.67. Pooled correlation coefficient =-0.54 (p,0.0001), χ2 test for heterogeneity =591 and I2 score for 
inconsistency =97.2%.
Abbreviation: FeV1, forced expiratory volume in 1 second.
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Further investigation into the cause of heterogeneity 
revealed major differences in the choice and combination 
of reconstruction algorithm, slice thickness and software 
program used by included studies. When meta-analysis 
was restricted to those studies using the same CT acquisi-
tion parameters, the forest plot became more uniform and 
heterogeneity reduced (Figure 3).
Seven studies performed multivariate linear regression 
between FEV
1
 and CT density (Table 3). However, for 
each density variable, all studies were adjusted for different 
variables and therefore an accurate meta-analysis could not 
be performed.
FeV1/forced vital capacity
Akin to FEV
1
, there was a significant correlation between 
each density variable and FEV
1
/forced vital capacity 
(p,0.0007; Table 4). Again, large visual and statistical 
heterogeneity was improved by restricting to studies using 
the same CT parameters (Figure 4).
gas transfer
A total of 23 studies compared DLCO percent predicted 
to CT density. The pooled correlation coefficients were 
universally significant across each of the density values, 
albeit slightly weaker than for FEV
1
 percent predicted and 
CT density (Table 5). The same pattern was seen regarding 
heterogeneity of results, with I2 dropping from 91.5% to 0 
once CT algorithm was taken into account (Figure 5).
Quality of life, symptom and composite 
scores
St Georges Respiratory Questionnaire (SGRQ) was the 
most frequently reported measure of QOL compared with 
CT density. A total of 2 out of 5 studies using correlation 
coefficients showed no relationship between the two 
measures, while the other 3 showed a strong association 
(p,0.003) (Table 6). There was variability in the density 
threshold and patient groups used (eg, cancer screening popu-
lations or those being considered for lung volume reduction 
surgery), thus precluding meta-analysis. Nevertheless studies 
that performed multivariate analyses consistently showed a 
significant association between density and SGRQ.
Studies of BMI, airflow obstruction, dyspnea and 
exercise capacity and Medical Research Council (MRC) 
versus CT density used different density thresholds and 
statistical techniques but again showed strong relationships 
between density and the score in question in multivariate 
analyses (Table 7).
longitudinal studies of CT density
Mortality
A total of 6 papers reported the relationship between CT 
density and mortality, 3 of which provided a hazard ratio 
for all-cause mortality (Table 8) generated by multi-variable 
logistic regression. However, it was inappropriate to combine 
them statistically due to differing emphysematous thresh-
olds and confounding variables included in their models. 
Emphysema as defined by CT density remained a significant 
independent predictor for mortality throughout.
exacerbations
A total of 4 studies investigated low CT density as a risk factor for 
COPD exacerbations using multiple regression analyses in order 
to independently attribute exacerbations to density loss (Table 9). 
Due to different statistical methods, and the variables adjusted 
for, a statistical meta-analysis could not be performed. All but 1 
study showed a significant relationship between CT density and 
exacerbations; Yoo et al found that the ability for emphysema 
Table 2 Summary of meta-analyses performed on all studies using Pearson’s correlation coefficient to compare FEV1 and FeV1 percent 
predicted with CT density
PFT Density  
variable
No of  
studies
SH pooled  
correlation
Lower  
95% CI
Higher  
95% CI
p-value I2 χ2 p-value
FeV1 -950 6 -0.37 -0.53 -0.21 ,0.0001 90.7 48.54 ,0.0001
-960 3 -0.33 -0.43 -0.22 ,0.0001 46.9 3.78 0.15
PD15 4 0.40 0.20 0.59 ,0.0001 84.9 18.90 0.0003
FeV1pp -900 3 -0.53 -0.63 -0.43 ,0.0001 0 1.96 0.37
-910 9 -0.29 -0.38 -0.20 ,0.0001 80.5 36.45 ,0.0001
-950 14 -0.54 -0.66 -0.42 ,0.0001 97.2 591.46 ,0.0001
-960 4 -0.35 -0.51 -0.19 0.0003 84.5 17.70 0.0005
PD15 4 0.45 0.27 0.63 ,0.0001 98.8 288.78 ,0.0001
Notes: SH weighted mean correlation coefficient, heterogeneity scores (I2) and chi-square values (χ2) are shown.
Abbreviations: FeV1, forced expiratory volume in 1 second; CT, computed tomography; SH, Schmidt-Hunter; CI, confidence interval; PD15, 15th percentile point; FEV1pp, 
forced expiratory volume in one second percent predicted; PFT, pulmonary function test.
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index to predict exacerbations did not remain significant when 
numerous variables such as age, SGRQ and Charlson Index 
score were included in multiple regression analysis.36 Cheng 
et al performed a multivariate ordinal logistic regression to 
demonstrate that %LAA .7.5 was associated with worse per-
formance status and MRC grade if they presented to Accident 
and Emergency with an infective exacerbation of COPD.37
Interventional studies reporting CT density
aaT augmentation therapy
A total of 3 RCTs used CT density as an outcome measure 
for augmentation therapy in AATD patients;9,41,42 change in 
CT density was the primary outcome in 2 studies41,42 and sec-
ondary outcome in the earliest work.9 A fourth paper was not 
included in the quantitative synthesis as it simply explored 
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Figure 3 The effect of CT algorithm on heterogeneity of results with respect to -950 hU and FeV1 percent predicted.
Notes: (A) Forest plot demonstrating individual Pearson’s correlation coefficients and pooled result for those studies comparing -950 hU and FeV1 percent predicted. 
SH weighted mean correlation coefficient =-0.54, I2=99.3%, χ2=587.85. (B) Forest plot demonstrating the effect on heterogeneity once the same reconstruction algorithm, 
slice thickness and software program were used. SH weighted mean correlation coefficient =-0.66, I2=91.8%, χ2=33.59.
Abbreviations: CT, computed tomography; FeV1, forced expiratory volume in 1 second; sh, schmidt-hunter.
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statistical approaches in data from the EXACTLE trial.43 
In all papers, CT density was log transformed and volume 
adjusted (see Table S3 for CT acquisition parameters), study 
duration was 2–3 years and the rate of density decline was 
measured in g/l-1 per year. A recent meta-analysis of these 
data has been reported separately, which demonstrates slower 
density decline in those receiving augmentation therapy than 
those receiving placebo (p=0.002).44 The 3 papers analyzed 
also report overall low to moderate correlation coefficients 
between CT density and FEV
1
, KCO and exercise tolerance 
(0.31, 0.47 and -0.21 respectively).
all-trans retinoic acid
All-trans retinoic acid was shown to promote alveolar repair 
in animal models and subsequently 2 studies examined its 
effect in AATD as measured by CT density. However, neither 
showed any significant benefit on density decline nor did 
either comment on the observed relationship between CT 
density and other clinical parameters.45,46
Inhaled long-acting beta agonist/inhaled 
corticosteroid
A total of 2 studies from South Korea and the KOLD study 
collected longitudinal data on spirometric change over 
3 months with inhaled corticosteroid/long-acting beta ago-
nist treatment and demonstrated a significant correlation 
between FEV
1
 and baseline CT density using -950 HU as 
the emphysematous threshold.47,48 Shaker et al performed 
annual CT densitometry in a RCT conducted in patients with 
COPD, which demonstrated significantly slower decline in 
emphysema (using -910 HU; p=0.02) in those randomized 
to budesonide compared to placebo.49
standardizing studies for equal CT variables
Since there were clear differences in the meta-analyses 
regarding the relationship between CT density and outcome 
when stratified by CT algorithm/statistical methods, we felt 
it was important to summarize the wide range of methods 
used in included studies (Figure 6).
Pulmo was the most frequently used software program 
(used in EXACTLE and RAPID trials), followed by Pulmo-
nary Workstation (used in COPDGene studies).
Most commonly, the reconstruction algorithm used was not 
mentioned, followed by “standard reconstruction algorithm”. 
The reconstruction algorithms are scanner specific, not always 
Table 3 summary of studies that performed multivariate linear 
regression analyses to examine the relationship between FeV1 and 
CT density
Density 
measure
Study Variables 
adjusted for
Results for 
adjusted FEV1
95 % CI
-950 hU Kim 
et al16
Mean wall area
Visual score of 
emphysema
Visual score of 
lobe no with 
aWT
β=-0.4726 -0.8215, -0.1238
Mohamed 
hoesein 
et al17
age
height
Pack years
smoking status
β=-0.252 –
hong 
et al18
%laa -950 hU
Mean lung density
Mean wall area
smoking status
β=-0.24 –
aziz 
et al19
DlCO
FeV1
β=-1.27 -1.59, -0.94
PD15 Mohamed 
hoesein 
et al20
age
FeV1/FVC
Medical center
Mucus production
smoking status
1 point change 
in PD15 results 
in a -0.824 ml 
3-year change 
in FeV1
-1.473, -0.0174
Mohamed 
hosein 
et al21
age
height
Medical center
smoking status
Years in study
1 hU change 
in PD15 results 
in a -4.75 ml 
3-year change 
in FeV1
-3.3, -6.1
Mohamed 
hoesein 
et al22
age
FeV1
Pack years
10 hU drop 
in Perc15 
caused a -10 ml 
change in FeV1
-15, -5
Note: ‘–’ indicates data not available.
Abbreviations: FeV1, forced expiratory volume in 1 second; CT, computed 
tomography; CI, confidence interval; AWT, airway wall thickness; %LAA, percentage 
low attenuation area; DlCO, diffusing capacity of the lungs for carbon monoxide; FVC, 
forced vital capacity; PD15, 15th percentile point.
Table 4 summary of studies comparing FeV1/FVC with CT density, divided up in to the most commonly reported thresholds
PFT Density  
variable
No of  
studies
SH pooled  
correlation
Lower  
95% CI
Higher  
95% CI
p-value I2 χ2 p-value
FeV1/FVC -910 5 -0.33 -0.49 -0.16 ,0.0001 95.5 75.72 ,0.0001
-950 14 -0.38 -0.53 -0.23 ,0.0001 95.6 251.72 ,0.0001
-960 3 -0.48 -0.71 -0.25 ,0.0001 88.9 18.73 ,0.0001
PD15 6 0.26 0.09 0.43 0.0022 94.9 81.78 ,0.0001
Note: heterogeneity score (I2), chi-square value (χ2) and SH weighted mean correlation coefficient are shown.
Abbreviations: FeV1/FVC, forced expiratory volume in 1 second/forced vital capacity; CT, computed tomography; SH, Schmidt-Hunter; CI, confidence interval; PD15, 15th 
percentile point.
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Figure 4 The effect of CT algorithm on heterogeneity of results with respect to PD15 and FeV1/FVC.
Notes: (A) Forest plot of all studies comparing FeV1/FVC with PD15. SH weighted mean correlation coefficient =-0.26, I2=94.9%, χ2=81.78. (B) Forest plot of all studies 
comparing FEV/FVC with PD15 using the same CT parameters. SH weighted mean correlation coefficient =-0.47, I2=4.1%, χ2=3.23.
Abbreviations: CT, computed tomography; PD15, 15th percentile point; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; sh, schmidt-hunter.
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%
clear and therefore would be difficult to reproduce. The most 
frequently used slice thicknesses were 1 mm (N=40) and 
sub-millimeter (N=20).
Bias assessment
Risk of bias is summarized in Table 10 (see Table S4 for 
the full risk of bias assessment). Bias introduced during 
patient selection was relatively low, with the patient source, 
selection and inclusion/exclusion criteria well described. The 
highest level of uncertainty that could have led to bias was 
within index and reference test (ie, CT and lung function). 
There was variability in the detail that authors gave with 
regards to CT acquisition, the use of a phantom and whether 
or not a bronchodilator was applied before spirometry was 
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Table 5 studies subdivided into density parameter used, which compares gas transfer to CT measured density
PFT Density  
variable
No of  
studies
SH pooled  
correlation
Lower  
95% CI
Higher  
95% CI
p-value I2 χ2 p-value
DlCO -950 5 -0.42 -0.53 -0.32 ,0.0001 77.8 15.538 0.0036
DlCOpp -910 3 -0.31 -0.40 -0.22 ,0.0001 83.6 10.46 0.005
-950 16 -0.43 -0.52 -0.34 ,0.0001 88 100.34 ,0.0001
PD15 5 0.29 0.15 0.42 ,0.0001 92.2 33.79 ,0.0001
KCO -950 3 -0.63 -0.71 -0.54 ,0.0001 49.9 4.43 0.1091
PD15 3 0.38 0.15 0.61 0.0012 96.4 45.67 ,0.0001
KCOpp -910 3 -0.61 -0.63 -0.59 ,0.0001 0 0.29 0.8658
-950 6 0.42 -0.6 -0.25 ,0.0001 78.6 22.47 0.0004
Note: heterogeneity score (I2); chi-square value (χ2) and SH weighted mean correlation coefficient are shown.
Abbreviations: CT, computed tomography; SH, Schmidt-Hunter; CI, confidence interval; DLCO, diffusing capacity of the lungs for carbon monoxide; pp, percent predicted; 
PD15, 15th percentile point; KCO, transfer factor divided by the alveolar volume.
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Figure 5 The effect of CT algorithm on heterogeneity of results with respect to PD15 and DlCO percent predicted.
Notes: (A) Forest plot demonstrating correlation coefficient confidence intervals and pooled correlation coefficient for those studies comparing DLCO percent predicted 
with PD15. SH weighted mean correlation coefficient =0.3, I2=91.5%, χ2=40.98. (B) Forest plot of those studies comparing PD15 and DlCO percent predicted once all studies 
using the same CT variables have been re-analyzed. SH weighted mean correlation coefficient =0.69, I2=0%, χ2=2.72.
Abbreviations: CT, computed tomography; PD15, 15th percentile point; DlCO, diffusing capacity of the lungs for carbon monoxide; sh, schmidt-hunter.
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Table 6 summary of studies that correlated CT density with sgrQ
References COPD or AATD %LAA parameter Statistical technique Results p-value
Univariate analysis
stolk et al23 aaTD PD15 spearman’s CC -0.56 ,0.007
-950 hU 0.6 0.003
Dowson et al24 aaTD -910 spearman’s CC 0.39 ,0.001
Barjaktarevic et al25 COPD -950 Pearson’s CC 0.028 0.572
Motohashi et al26 COPD -940 Pearson’s CC 0.501 ,0.001
de Torres et al27 COPD -960 Pearson’s CC -0.12 0.39
Martinez et al28 COPD -950 Un-normalized and 
normalized (value – 
mean/sD) parameters in 
univariate analysis
Un-normalized estimate
0.53 (95% CI 0.45, 0.61)
,0.001
normalized estimate
5.82 (95% CI 4.91, 6.72)
,0.001
Multivariate analysis
Martinez et al29 COPD -950 adjusted for age, pack years 
and FeV1 percent predicted
Beta value =-7.69 
(95% CI -14.09, -1.3)
0.02
gietema et al30 COPD -950 adjusted for sex, age, 
smoking status, pack years, 
BMI and FeV1 percent 
predicted and Pi10
Coefficient =1.43
se =0.57
,0.05
Abbreviations: CT, computed tomography; sgrQ, st georges respiratory Questionnaire; COPD, chronic obstructive pulmonary disease; aaTD, alpha-1 antitrypsin 
deficiency; %LAA, percentage low attenuation area; PD15, 15th percentile point; CC, correlation coefficient; SD, standard deviation; CI, confidence interval; BMI, body mass 
index; FeV1, forced expiratory volume in 1 second; Pi10, 10 mm luminal perimeter; se, standard error.
Table 7 summary of studies that compare BODe and MrC with CT density, subdivided into univariate or multivariate models used
References COPD or AATD Severity measure %LAA Statistical technique Results p-value
Univariate analysis
Camiciottoli et al31 COPD BODe -950 Pearson’s CC R=0.58 ,0.0001
Martinez et al28 COPD BODe -950 Un-normalized and normalized 
(value – mean/sD) parameters in 
univariate analysis
Un-normalized estimate 
1.02 (95% CI 1.02–1.02)
,0.001
normalized estimate
1.23 (95% CI 1.2–1.26)
,0.001
de Torres et al27 COPD BODe -960 Pearson’s CC R=-0.08 0.53
Camiciottoli et al6 COPD MrC -950 Odds ratio 1.41 (95% CI 1.11–1.78) ,0.005
haruna et al32 COPD MrC -960 Pearson’s CC R=0.41 ,0.05
haruna et al33 COPD MrC -960 Pearson’s CC 0.41 ,0.05
de Torres et al27 COPD MrC -960 Pearson’s CC R=-0.19 0.14
Multivariate analysis
Martinez et al29 COPD BODe -910 adjusted for age, pack years and 
FeV1% predicted
Beta value =0.01
7.69 (95% CI 0.005, 
0.02)
0.002
Camiciottoli et al31 COPD BODe -950 adjusted for FeV1, BMI, MrC, 6MWT R=0.61 ,0.0001
haruna et al32 COPD MrC -960 adjusted for FeV1, rV/TlC
 r5-r20, X5
R=0.06 ,0.05
Abbreviations: BODE, BMI, airflow obstruction, dyspnea and exercise tolerance; MRC, Medical Research Council; CT, computed tomography; COPD, chronic obstructive 
pulmonary disease; AATD, alpha-1 antitrypsin deficiency; %LAA, percentage low attenuation area; CC, correlation co-efficient; SD, standard deviation; CI, confidence 
interval; MrC, Medical research Council; 6MWT, 6-minute walk test; FeV1, forced expiratory volume in 1 second; rV/TlC, residual volume/total lung capacity; r5-r20, 
measure of airway resistance at 5 and 20 hz; X5, airway reactance at 5 hz.
performed. Missing data and confounding variables were 
often not accounted for, but the statistical tests applied were 
considered appropriate.
Publication bias
The funnel plots for -959 HU versus FEV
1
 percent pre-
dicted and DLCO percent predicted (analyses containing 
the most studies) show a significant degree of publication 
bias (Figure 7). On further inspection of both plots, there 
is one study with a low standard error and large popula-
tion (Washko et al) that causes the funnel plots to shift to 
the right.50 Without this study, it stands to reason that the 
funnel would be more inclusive of the studies within the plot 
and could imply less publication bias. The risk of bias by 
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Table 9 summary of papers describing the association between CT density and exacerbations, subdivided into the risk of exacerbations 
from a low density score, and the impact exacerbations have on CT density decline
References %LAA parameter Statistical technique Variable adjusted for Results p-value
Yoo et al36 -950 Univariate logistic 
regression
Or =1.02
(95% CI 1.01, 1.04)
0.01
Multiple logistic 
regression
sex, gender, current smoker, 
exacerbation leading to hospitalization 
in past year, Charlson index, BMI, 
MMrCs, 6MWD, sgrQ, FeV1%, CT 
wall area %, CT air trapping index
Or =1.01
(95% CI 0.987, 1.034)
0.39
Vijayasaratha 
and 
stockley38
PD15 stepwise linear 
regression; 
spearman’s CC
FeV1, FeV/FVC, KCO% predicted, 
delay in treatment initiation in days, 
anthonisen criteria, cold symptoms
PD15 associated with 
exacerbation length and
(r=-0.361)
0.003
Treatment delay (r=-0.786) 0.004
Mcallister 
et al39
-910 Multivariate rr age, sex, race/ethnicity and cotinine % emphysema predicts 
episodes of care
rr 1.45 (95% CI 1.04, 2.03)
0.03
↑hospital admissions
rr 1.62 (95% CI 1.08, 2.44)
0.02
han et al40 -950 Multivariate analyses 
and forward selection 
regression
scanner model, age, sex, smoking 
status and FeV1
.35% emphysema 
associated with a 1.18-fold 
increase in exacerbation
0.047
5% ↑in emphysema 
associated with a 0.86-fold 
↑in exacerbation frequency
0.001
Note:↑ represents as increased.
Abbreviations: CT, computed tomography; %LAA, percentage low attenuation area; OR, odds ratio; CI, confidence interval; BMI, body mass index; MMRCS, Modified 
Medical research Council Dyspnea scale; 6MWD, 6-minute walk distance; sgrQ, st georges respiratory Questionnaire; FeV1, forced expiratory volume in 1 second; PD15, 
15th percentile point; CC, correlation co-efficient; FVC, forced vital capacity; KCO, transfer factor divided by the alveolar volume; RR, rate ratios.
Table 8 Studies reporting an all-cause mortality HR for emphysema as defined by CT density
References Patient 
source
%LAA Statistical technique Confounding 
variables in model
Results HR Lower 
CI
Upper 
CI
p-value
haruna 
et al33
COPD 
OPa 
clinic
-960 Univariate and multivariate 
Cox proportional hazards
Univariate analysis and 
therefore n/a
↑%LAA significantly 
related to mortality
1.52 1.2 1.91 ,0.001
Upper lung field 1.55 1.22 1.95 ,0.001
Lower lung field 1.41 1.09 1.78 0.009
age, BMI, FeV1, rV/TlC 
and KCO
%laa independent 
predictor of mortality
1.74 1.18 2.54 ,0.01
Martinez 
et al34
neTT -950 Univariate and multivariate 
Cox proportional hazards
n/a Whole lung % emphysema 
not associated with 
mortality
1.14 0.85 1.52 0.38
lower zone emphysema 
associated with ↑mortality
1.39 1.04 1.85 0.02
age, lTOT, hb, 
BODe, rV%, TlC%, 
DlCO%, maximal CPeT 
workload, lower lung 
emphysema and nuclear 
perfusion scan result
Difference between 
upper and lower lungs 
% emphysema remained 
predictive in multivariate 
model
1.80 1.22 2.66 0.003
Dawkins 
et al35
aDaPT -910 Univariate Cox 
proportional hazards
age
hr for mortality (exp B) 
comparing those with 
FeV1 .80 pp with 
FeV1 ,30 pp
survival curves indicate 
a relationship of ↑VI to 
↑mortality
↑%laa associated with 
↑mortality
0.111 0.026 0.473 0.003
Note:↑ represents as increased.
Abbreviations: HR, hazard ratio; CT, computed tomography; %LAA, percentage low attenuation area; CI, confidence interval; COPD, chronic obstructive pulmonary 
disease; n/a, not applicable; BMI, body mass index; FeV1, forced expiratory volume in 1 second; rV, residual volume; TlC, total lung capacity; KCO, transfer factor divided 
by the alveolar volume; LTOT, long-term oxygen therapy; Hb, hemoglobin; BODE, BMI, airflow obstruction, dyspnea and exercise tolerance; DLCO, diffusing capacity of the 
lungs for carbon monoxide; CPeT, cardiopulmonary exercise testing; pp, percent predicted; VI, voxel index; OPa, outpatient; neTT, national emphysema Treatment Trial; 
ADAPT, Antitrypsin Deficiency Assessment and Programme for Treatment.
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Figure 6 (Continued)
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Figure 6 (A) Bar chart to demonstrate variety of software programs used in all studies. (B) Bar chart to demonstrate the variety of reconstruction algorithms reported. 
(C) Bar chart to demonstrate variety of slice thicknesses reported in all studies.
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two independent reviewers of this study was concluded as 
moderate, based on no mention of the time interval between 
the CT and pulmonary function tests. There was also no 
explanation of how confounding variables were assessed or 
controlled for, or how missing data were handled.
Discussion
The purpose of this review was to summarize all the currently 
available literature regarding CT density and its associa-
tion with commonly used clinical parameters to develop a 
clear understanding of the utility of CT density measures 
for current and future clinical practice. This is particularly 
important as CT density has been used as a primary outcome 
in registration level clinical trials in AATD, but doubt has 
been cast by some authors as to its relevance as a surrogate 
outcome.41,51 Our data showed that association between CT 
density and other clinical parameters deemed suitable as 
outcomes for airways disease trials (eg, FEV
1
, SGRQ) were 
consistently significant, and furthermore there was a clear 
and consistent relationship to mortality. This suggests that CT 
density is an appropriate surrogate outcome measure in stud-
ies of emphysema, like those conducted in AATD. However, 
publication and other biases as well as study heterogeneity 
make it more difficult to draw conclusions regarding the 
precise strength of each relationship.
Over half of the included studies were from larger cohort 
studies and subsequent retrospective/cross-sectional analysis. 
The nature of these cohorts introduces heterogeneity in the 
types of patients recruited, ie, lung cancer screening studies 
(NELSON),52 alpha one cohorts,53 COPD (eg, COPDGene, 
KOLD15,54) and end-stage disease (eg, NETT).55 The consis-
tency of direction of the relationship between density and 
lung function across diverse patient groups is reassuring 
and suggests that density could be a valid surrogate outcome 
across the spectrum of disease severity. However, the wide 
range of values seen for the CT versus FEV
1
 correlations 
Table 10 summary of the risk of bias assessment
Risk of bias Low High Unclear
Patient selection 81 (72) 8 (7) 24 (21)
Index and reference test 36 (32) 8 (7) 69 (61)
Flow and timing 60 (53) 28 (25) 25 (22)
reporting 59 (52) 39 (35) 15 (13)
Note: Data presented as number of studies (% of studies).
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Figure 7 (A) Funnel plot for studies correlating -950 hU with FeV1 percent predicted. (B) Funnel plot for studies correlating -950 hU with DlCO percent predicted.
Abbreviations: FeV1, forced expiratory volume in 1 second; DlCO, diffusing capacity of the lungs for carbon monoxide.
meant that defining the exact level of CT density that relates 
to, for instance, the minimal clinically important difference 
(MCID) for FEV
1
 was difficult.
The chosen CT parameter (eg, -950 HU, 15th percentile 
point [PD15]), software program, reconstruction algorithm 
and slice thickness varied grossly throughout. This level of 
heterogeneity was far greater than we had anticipated and 
made combination of all data via meta-analysis potentially 
less valid. The broad range of published correlation coef-
ficients seen between -950 HU and FEV
1
% (Figure 2) 
(from -0.1 to -0.8) demonstrated this well, and when only 
studies with the same CT acquisition variables were analyzed, 
the level of heterogeneity fell dramatically. This implies 
that future CT density studies should have a standardized 
approach. Despite PD15 being established as the most 
reliable and sensitive measure, we have seen many studies 
that do not use this parameter, and would encourage authors 
to report this value so that data can be combined and our 
knowledge can grow.
The most appropriate CT algorithm would be a soft recon-
struction algorithm (eg, B30f), slice thickness 2.5–5 mm 
and a software program that yields reliable and repeatable 
results. The algorithm and slice thickness are optimal due 
to minimal technical noise. Sharper algorithms and thinner 
slices have been demonstrated to overestimate the amount 
of emphysema.56 Many publications used in-house software 
that, while producing useful data, may not be comparable to 
one another.57 For example, Pulmo and Pulmonary Work-
station are two of the most commonly used software pro-
grams (used in RAPID trial and COPDGene cohort studies, 
respectively), and if identical and repeatable results can be 
produced by both programs then cohort studies using them 
can then be combined and meta-analyzed to increase power. 
This requires direct comparison of the software on the same 
scans; a similar approach would be needed for slice thick-
ness, reconstruction and so on. There are limited studies of 
this nature to date.7
There was a paucity of longitudinal CT density data in 
the included studies, which precluded conclusions about the 
sensitivity and specificity of CT density change over time 
with respect to our chosen outcomes. This means that we 
are unable to assess the relationship between CT density and 
clinical parameters over time for which there was a known 
MCID (eg, FEV of 100 mL), and therefore a proposal of a 
MCID for CT density was not possible. This would be of 
particular use for registration level trials, which have used 
or intend to use this as their primary outcome.
The key strengths of this review are that it was very 
broad; therefore, all potential papers were captured. Rigorous 
checking of data extracted from the large number of included 
studies was done, and the statistical analyses were conducted 
under supervision of an experienced statistician. Limitations 
were largely centered on the quality and heterogeneity of 
the included studies. There are other CT scanner variables 
that we did not examine in more detail as their impact was 
considered less relevant, eg, scanner type and radiation dose. 
There were 14 papers in languages to which we did not have 
access to a translator such as Japanese and Korean.
Conclusion
This evidence synthesis has demonstrated that CT density 
relates significantly to all commonly used clinical param-
eters. However, the large amount of heterogeneity and lack 
of longitudinal data mean that how sensitive and specific 
CT density is to change relating to time or interventions is 
not clear. We recommend that international consensus be 
reached to standardize CT conduct and analysis in future 
emphysema studies.
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